The week in industry: first and only transdermal patch formulation for schizophrenia approved
This week: Partnership to identify novel ALS and FTD treatments, US$56 million to accelerate rare diseases program and DNA-encoded library-based drug discovery collaboration announced.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>